01 — At a Glance
The Pharma King Who Just Tripped on Stairs
- 52-Week High / Low₹1,673 / ₹1,282
- Q3 FY26 Revenue₹7,074 Cr
- Q3 FY26 PAT₹884 Cr (Flat YoY)
- Quarterly EPS₹8.37
- Annualised EPS (Q3×4)₹33.48
- Book Value₹408
- Price to Book3.24x
- Dividend Yield0.98%
- Net Cash Position₹10,229 Cr
- Return (3 Months)-13.1%
The Headline: Cipla reported Q3 FY26 revenue of ₹7,074 crore (flat YoY), PAT of ₹884 crore, and EPS of ₹8.37. But here’s the thing: the real story isn’t in the earnings. It’s in the two elephants standing in the boardroom. Lanreotide production is halted. Revlimid is dying. And the stock has crashed 13% in three months. Management says “transition year.” Analysts say “pray.”
02 — Introduction
The Pharma Giant Playing Russian Roulette with Two Bullets
Cipla is India’s third-largest pharmaceutical company by market share. It makes respiratory drugs that doctors swear by, anti-infectives that save lives, and in the US market, some obscure generic drugs that make extraordinary money. Founded in 1935 by Yusuf Hamied — India’s own pharmaceutical freedom fighter — Cipla has spent 90 years quietly becoming the backbone of generic pharma globally.
But Q3 FY26 just walked in and kicked the legs out from under that legacy. Two of Cipla’s biggest cash generators are simultaneously imploding. Generic Revlimid (lenalidomide) — a ₹1,000+ crore annual revenue earner — is facing patent cliff and declining rapidly. And Lanreotide, the company’s second-largest revenue contributor, just went into production arrest because its supplier in Greece got slapped with an FDA OAI (Official Action Indicated) status. That’s pharma-speak for “your facility is broken, figure it out.”
Management went on the January 2026 concall and said everything is “transition year” and “pipeline looks closer.” Translation: pray that US respiratory launches happen on time, or this stock will crack like a dropping egg.
So what’s actually happening inside Cipla? Is this the beginning of a reset, or the start of a value destruction story? Let’s dig through the data, the drama, and the real operational issues. Because right now, at a 22.4x P/E with margin compression and two product cliffs, the math doesn’t defend the valuation.
Concall Context (Jan 2026): Management acknowledged “lower-than-anticipated Lanreotide performance” and that EBITDA was “1.5–2% below internal expectations” due to supply issues and planned R&D spend increases for US launches.
03 — Business Model: Pills, Generics & Prayers
How Does Cipla Actually Make Money?
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
